Cue Biopharma News

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T

GlobeNewswireApr 24 10:01 ET

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

Yahoo FinanceApr 15 09:55 ET

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

Throughout the last three months, 4 analysts have evaluated Cue Biopharma (NASDAQ:CUE), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings,

BenzingaApr 9 10:01 ET

Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning

TipRanksApr 9 09:35 ET

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Dow JonesApr 9 08:56 ET

Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target

Oppenheimer analyst Leland Gershell maintains Cue Biopharma (NASDAQ:CUE) with a Outperform and maintains $10 price target.

BenzingaApr 9 08:22 ET

Oppenheimer Remains a Buy on Cue Biopharma (CUE)

TipRanksApr 9 07:35 ET

Cue Biopharma (CUE) Gets a Buy From Stifel Nicolaus

TipRanksApr 9 07:07 ET

Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...

Yahoo FinanceApr 9 03:02 ET

Earnings Call Summary | Cue Biopharma(CUE.US) Q4 2023 Earnings Conference

The following is a summary of the Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript:Financial Performance:Cue Biopharma reported collaboration revenue of approximately $1.8 million in Q4, pri

moomoo AIApr 8 22:03 ET · Conference Call

Cue Biopharma Q1 EPS $(0.28) Misses $(0.27) Estimate, Sales $1.82M Beat $1.13M Estimate

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.27) by 3.7 percent. This is a 3.45 percent increase over losses of $(0.29)

BenzingaApr 8 16:06 ET

Cue Biopharma 4Q Loss/Shr 28c >CUE

Cue Biopharma 4Q Loss/Shr 28c >CUE

Dow JonesApr 8 16:05 ET

Press Release: Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stag

Dow JonesApr 8 16:05 ET

Calendar of U.S. Earnings Expected in the Week Ahead

Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo

Dow JonesApr 8 06:00 ET

Notable Earnings After Monday's Close

Seeking AlphaApr 7 17:35 ET

Cue Biopharma Price Target Maintained With a $8.00/Share by Piper Sandler

Cue Biopharma Price Target Maintained With a $8.00/Share by Piper Sandler

Dow JonesApr 3 12:11 ET

Express News | Piper Sandler Reiterates Overweight on Cue Biopharma, Maintains $8 Price Target

Moomoo 24/7Apr 3 12:01 ET

Piper Sandler Remains a Buy on Cue Biopharma (CUE)

TipRanksApr 3 07:06 ET

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate dis

GlobeNewswireApr 2 08:00 ET

Jefferies Starts Cue at Buy, Cites Partnering Potential

Seeking AlphaMar 13 14:55 ET